Exploring Canine Mammary Cancer through Liquid Biopsy: Proteomic Profiling of Small Extracellular Vesicles

• Published in: Cancers Vol. 16; no. 14; p. 2562
• Main Authors: Novais, Adriana Alonso, Tamarindo, Guilherme Henrique, Melo, Luryan Mikaelly Minotti, Balieiro, Beatriz Castilho, Nóbrega, Daniela, Dos Santos, Gislaine, Saldanha, Schaienni Fontoura, de Souza, Fabiana Ferreira, Chuffa, Luiz Gustavo de Almeida, Bracha, Shay, Zuccari, Debora Aparecida Pires de Campos
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17.07.2024
• Subjects: Actin; Alfacalcidol; Analysis; Biomarkers; Biopsy; Breast cancer; Calcifediol; Cancer; Development and progression; Diagnosis; Disease; Dogs; Ethylenediaminetetraacetic acid; Exosomes; Extracellular vesicles; Females; Gelsolin; Invasiveness; Laboratories; Liquid chromatography; Mass spectrometry; Mass spectroscopy; Mastectomy; Medical screening; Metastasis; Nanoparticles; Oncology, Experimental; Phosphopyruvate hydratase; Plasma; Protein binding; Proteins; Proteomics; Remission; Remission (Medicine); Scientific imaging; Translation elongation; Translation elongation factor 2; Transmission electron microscopy; Transthyretin; Trypsin; Tumors; Ultracentrifugation; Veterinary medicine; Vitamin D; Vitamin D-binding protein; Brazil; United States > US; proteomics; mammary carcinoma; diagnosis; canine; small extracellular vesicles; biomarker; liquid biopsy
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16142562

(Background). Canine mammary tumors (CMTs) have emerged as an important model for understanding pathophysiological aspects of human disease. Liquid biopsy (LB), which relies on blood-borne biomarkers and offers minimal invasiveness, holds promise for reflecting the disease status of patients. Small extracellular vesicles (SEVs) and their protein cargo have recently gained attention as potential tools for disease screening and monitoring. (Objectives). This study aimed to isolate SEVs from canine patients and analyze their proteomic profile to assess their diagnostic and prognostic potential. (Methods). Plasma samples were collected from female dogs grouped into CMT (malignant and benign), healthy controls, relapse, and remission groups. SEVs were isolated and characterized using ultracentrifugation (UC), nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM). Proteomic analysis of circulating SEVs was conducted using liquid chromatography-mass spectrometry (LC-MS). (Results). While no significant differences were observed in the concentration and size of exosomes among the studied groups, proteomic profiling revealed important variations. Mass spectrometry identified exclusive proteins that could serve as potential biomarkers for mammary cancer. These included Inter-alpha-trypsin inhibitor heavy chain (ITIH2 and ITI4), phosphopyruvate hydratase or alpha enolase (ENO1), eukaryotic translation elongation factor 2 (eEF2), actin (ACTB), transthyretin (TTR), beta-2-glycoprotein 1 (APOH) and gelsolin (GSN) found in female dogs with malignant tumors. Additionally, vitamin D-binding protein (VDBP), also known as group-specific component (GC), was identified as a protein present during remission. (Conclusions). The results underscore the potential of proteins found in SEVs as valuable biomarkers in CMTs. Despite the lack of differences in vesicle concentration and size between the groups, the analysis of protein content revealed promising markers with potential applications in CMT diagnosis and monitoring. These findings suggest a novel approach in the development of more precise and effective diagnostic tools for this challenging clinical condition.